WO2024254507A3 - Treatment of b cell lymphomas with nk cells and a cd20 targeted antibody - Google Patents

Treatment of b cell lymphomas with nk cells and a cd20 targeted antibody Download PDF

Info

Publication number
WO2024254507A3
WO2024254507A3 PCT/US2024/033083 US2024033083W WO2024254507A3 WO 2024254507 A3 WO2024254507 A3 WO 2024254507A3 US 2024033083 W US2024033083 W US 2024033083W WO 2024254507 A3 WO2024254507 A3 WO 2024254507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
treatment
cell lymphomas
targeted antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033083
Other languages
French (fr)
Other versions
WO2024254507A2 (en
Inventor
Fred ASLAN
Thorsten Graef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artiva Biotherapeutics Inc
Original Assignee
Artiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artiva Biotherapeutics Inc filed Critical Artiva Biotherapeutics Inc
Publication of WO2024254507A2 publication Critical patent/WO2024254507A2/en
Publication of WO2024254507A3 publication Critical patent/WO2024254507A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided herein are, among other things, methods for treatment of B Cell Lymphomas with NK cells and a CD20 targeted antibody.
PCT/US2024/033083 2023-06-09 2024-06-07 Treatment of b cell lymphomas with nk cells and a cd20 targeted antibody Pending WO2024254507A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507393P 2023-06-09 2023-06-09
US63/507,393 2023-06-09

Publications (2)

Publication Number Publication Date
WO2024254507A2 WO2024254507A2 (en) 2024-12-12
WO2024254507A3 true WO2024254507A3 (en) 2025-01-30

Family

ID=93796421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033083 Pending WO2024254507A2 (en) 2023-06-09 2024-06-07 Treatment of b cell lymphomas with nk cells and a cd20 targeted antibody

Country Status (1)

Country Link
WO (1) WO2024254507A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121505B (en) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 Chimeric antigen receptors and natural killer cells expressing them
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133057A1 (en) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd20 targeted antibody
WO2022216811A2 (en) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133057A1 (en) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd20 targeted antibody
WO2022216811A2 (en) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same

Also Published As

Publication number Publication date
WO2024254507A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2024254507A3 (en) Treatment of b cell lymphomas with nk cells and a cd20 targeted antibody
EP4549582A3 (en) Methods for spatial analysis using targeted rna depletion
EP4265568A3 (en) Process for preparing a secondary battery
WO2022272292A3 (en) Engineered cells for therapy
WO2021257989A3 (en) Methods and compositions for modulating cells and cellular membranes
EP4319772A4 (en) Treatment of cancer with nk cells and an egfr targeted antibody
EP4319769A4 (en) Treatment of cancer with nk cells and a cd20 targeted antibody
WO2023122755A3 (en) Flow cells and methods
MX2023014073A (en) T cell receptors targeting ras mutations and uses thereof.
WO2022150610A3 (en) Sars-cov-2-specific t cell receptors and related materials and methods of use
EP4383362A4 (en) Cathode material, battery using said cathode material, and method for charging battery
EP4310956A4 (en) Carbon material composition, method for producing carbon material composition, negative electrode, and secondary battery
MX2022004443A (en) Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma.
MX2025005088A (en) Methods of treating cancers
WO2021146620A3 (en) Chimeric antigen receptors for removal of amyloid
CR20230490A (en) Anti-cldn4/anti-cd137 bispecific antibody
WO2023086906A3 (en) Sirp gamma antibodies and uses thereof
MX2020003395A (en) Compositions and methods for treating diffuse large b cell lymphoma.
WO2023081455A3 (en) Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same
WO2021203061A8 (en) Stem cell immunomodulatory therapy for covid-19 infection
EP4148831A4 (en) Positive electrode active material precursor for lithium secondary battery, method for producing positive electrode active material precursor for lithium secondary battery, and method for producing positive electrode active material for lithium secondary battery
EP4207370A4 (en) Positive-electrode active material for nonaqueous-electrolyte secondary cell, and nonaqueous-electrolyte secondary cell
MX2021005847A (en) SUICIDE GENE.
WO2022212525A9 (en) Car t cell therapy and ifn gamma
WO2022226346A3 (en) Stable production systems for lentiviral vector production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820165

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE